LifeMD, Inc. (LFMD) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with revenue and EBITDA growth, no debt, and a positive cash position. The Q&A reveals robust demand for the Wegovy pill, promising initial retention rates, and strategic investments in growth areas like women's health. While management was vague on some specifics, the overall sentiment remains positive due to strong financial metrics, optimistic guidance, and strategic partnerships, despite some uncertainties.
Key Financial Performance
Revenue (Q4 2025) $46.9 million, a 4% increase year-over-year, driven by strong telehealth subscriber growth and branded therapy penetration in weight management.
Active Subscribers (Q4 2025) 323,000, a 16% increase year-over-year, reflecting strong business momentum and growth in weight management and men's health.
Gross Margin (Q4 2025) 87.1%, an expansion of 570 basis points year-over-year, due to revenue mix and operational efficiency.
Gross Profit (Q4 2025) $40.8 million, an 11% increase year-over-year, attributed to higher revenue and improved margins.
GAAP Net Income (Q4 2025) $19 million or $0.41 per share, including a one-time benefit from the sale of WorkSimpli. Excluding this, GAAP net loss was $1.9 million or $0.04 per share, compared to a loss of $6.8 million or $0.16 per share in Q4 2024.
Adjusted EBITDA (Q4 2025) $4.8 million, up from $1.1 million in Q4 2024, reflecting improved operational performance.
Revenue (Full Year 2025) $194.1 million, a 25% increase year-over-year, driven by growth across business lines.
Gross Margin (Full Year 2025) 85.7%, a slight decrease of 50 basis points year-over-year, due to revenue mix.
Gross Profit (Full Year 2025) $166.3 million, a 25% increase year-over-year, aligned with revenue growth.
GAAP Net Income (Full Year 2025) $11.2 million or $0.25 per share, including a one-time benefit from the sale of WorkSimpli. Excluding this, GAAP net loss was $13.3 million or $0.30 per share, compared to a loss of $26.3 million or $0.64 per share in 2024.
Adjusted EBITDA (Full Year 2025) $15.3 million, up from $3.7 million in 2024, reflecting improved operational efficiency and revenue growth.
Cash and Debt (End of 2025) $36.8 million in cash and no debt, providing financial flexibility for growth investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Weight Management: Record patient acquisition volumes with new sign-ups approaching 700 per day. Launched oral Wegovy in collaboration with Novo Nordisk, expanding access for patients preferring oral options.
Women's Health: Launched a virtual concierge women's health offering focused on menopause, perimenopause, hormonal health, and bone health. Collaborated with recognized experts like Dr. Doug Lucas and Dr. Tara Scott. Upcoming catalysts include insurance and Medicare support, pharmacy bundles, and strategic media programs.
Men's Health: RexMD brand returned to growth with 215,000 active patients. Expanded offerings to include insomnia, erectile dysfunction, dermatology, and topical pain relief. Integrated NovoCare for injectable and oral Wegovy.
Virtual Cardiology: Beta launched a 30-state virtual cardiology program with AI-supported intake processes for efficient diagnosis and treatment.
Pharmaceutical Collaborations: Deepened partnerships with Novo Nordisk and Eli Lilly. Exploring opportunities with other pharmaceutical companies.
Insurance Enablement: Platform covers over 110 million lives, expected to grow to 220 million by Q2 2026 through expanded partnerships.
AI Integration: Developed AI clinical decision support tools for personalized treatment recommendations. Embedded AI into operational workflows to improve efficiency and reduce overhead.
Pharmacy Infrastructure: Licensed in all 50 states, processing 20,000 prescriptions per month. Added 503-A compounding operation for personalized medications.
Technology Platform: Investing in a seamless platform experience integrating AI and insurance benefits. Modernizing systems for scalability and efficiency.
Growth Investments: Leveraging strong balance sheet to invest in patient acquisition and infrastructure, aiming for long-term growth and margin expansion.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Compliance: The company is closely following FDA guidance on peptide therapies, which indicates potential regulatory hurdles and uncertainties in launching new treatments.
Operational Efficiency: The company is embedding AI and automation into workflows to handle more volume without proportional increases in overhead, but this requires significant investment and could face implementation challenges.
Insurance Integration: The company is expanding insurance coverage to over 220 million lives, but this infrastructure expansion could face delays or operational challenges.
Customer Acquisition Costs (CACs): While CACs have declined, the company is making discretionary investments in patient acquisition, which could strain financials if returns are not realized as expected.
Pharmacy Operations: The company’s reliance on its 503-A compounding pharmacy for personalized medications introduces risks related to operational scalability and regulatory compliance.
AI Deployment: The company is heavily investing in AI for clinical decision support and personalized medicine, but this strategy depends on successful implementation and data integration, which could face technical or operational risks.
Market Competition: The company operates in highly competitive markets like weight management and virtual health, which could impact its ability to maintain or grow market share.
Economic Conditions: Economic uncertainties could impact patient spending on discretionary health services, affecting revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Weight Management Growth: LifeMD anticipates significant long-term growth in weight management, driven by the launch of oral Wegovy and collaborations with Novo Nordisk and Eli Lilly. The company expects record patient acquisition volumes in the first quarter of 2026, with new sign-ups approaching 700 per day.
Women's Health Expansion: LifeMD expects women's health to be a meaningful contributor to growth in 2026 and a major driver in the long term. Upcoming catalysts include the launch of insurance and Medicare support, pharmacy bundles, and strategic media and influencer programs.
Men's Health Growth: LifeMD plans to expand RexMD's clinical offerings with five new treatments in the first half of 2026, including insomnia, erectile dysfunction, dermatology, and topical pain relief. The company is also prepared to launch FDA-compliant peptide therapies.
Pharmacy Infrastructure: LifeMD's affiliate pharmacy, licensed in all 50 states, is expected to drive growth and expand margins. The company plans to leverage its 503-A compounding operation to produce personalized medications at scale.
AI Integration: LifeMD plans to launch an AI clinical decision support tool in the first half of 2026, aimed at improving patient acquisition, consult efficiency, and personalized medicine. The company sees AI as a major differentiator and growth driver.
Insurance Benefits Expansion: LifeMD expects to expand its insurance coverage to over 220 million lives by the end of Q2 2026, which is anticipated to reduce customer acquisition costs and improve retention.
Revenue and EBITDA Projections: For 2026, LifeMD projects revenue between $220 million and $230 million, with adjusted EBITDA between $12 million and $17 million. By Q4 2026, the company expects an annualized revenue run rate exceeding $250 million and adjusted EBITDA exceeding $25 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the demand for the Wegovy pill and brand products compared to 3Q and 4Q of '25 heading into 1Q of '26?
A:The demand has been very strong since the product launched in early January, nearly doubling new patient acquisition in the weight loss business, driven by the Wegovy pill. Encouraging unit economics led to increased spending on new patient acquisition.
Q:What is the revenue model for the Wegovy pill, and can you provide details on pricing and gross margins?
A:The Wegovy pill is priced at $249 a month as a bundle, with gross margins of approximately $100 per order. The product is treated as a pass-through, with margins derived from additional services provided to patients.
Q:What investments are being made in 1Q of '26 to create the EBITDA margin phenomenon?
A:The sales and marketing line will increase to $30 million to low $30s in 1Q, up from $20-$22 million in '25. CAC is reducing by 4%-5% sequentially, while volumes are doubling. Incremental dollars from volume will pay back in the back half of '26.
Q:What will drive the revenue ramp from 1Q to 4Q of '26?
A:The revenue ramp will be driven by subscriber count growth, particularly in the GLP-1 weight business, growth in the women's health business, and consistent growth in the Rx business.
Q:How much of the $25 million annualized EBITDA by exiting '26 will come from women's health, weight management, and cross-care pharmacy?
A:Women's health will add around $10 million in revenue in its first year but will not be EBITDA positive. EBITDA accretion will come from scaling subscriber counts in mature men's health and weight management businesses, with women's health becoming accretive in 2027.
Q:How does women's health compare to other markets in terms of CAC, conversion to care plans, and early retention?
A:Women's health has shown higher intent on CPC but struggled with conversion rates. CPA has been cut in half recently, and early retention rates are over 80%, indicating strong demand and a promising value proposition.
Q:What level of stickiness are you seeing with people on the Wegovy pill versus the injectable?
A:It is too early to determine long-term retention, but initial on-therapy rates and retention rates are better than the injectable due to the attractive price point of $149 and strong demand.
Q:How does your weight management platform compare to competitors like Lilly and Amazon?
A:LifeMD differentiates itself with its 50-state provider group, portfolio of specialty care, and synchronous care options. It offers highly trained providers and a broader range of services compared to competitors like Amazon.
Q:Are there any changes in patient acquisition channels or marketing strategies in Q1?
A:The strategy remains similar, with new media partnerships and smaller employer programs driving patient acquisition. Significant partnerships with large companies are also in the pipeline.
Q:What is the potential lifetime value of a covered patient versus a cash pay patient?
A:Retention is expected to be stronger for patients using insurance, potentially leading to better LTVs. However, the insurance business is new, and more data is needed to confirm this.
Q:What is the total number of subscribers, and how many are specifically for the Wegovy pill?
A:There are 322,000 overall subscribers, with 80,000+ in weight management. The exact number for the Wegovy pill is not disclosed but is driving significant new patient demand.
Q:What percentage of RexMD and Shapiro MD fulfillment is handled in-house, and what is the incremental margin lift?
A:Approximately 70% of fulfillment is handled in-house, with a margin improvement of 150-200 basis points. In-house fulfillment also provides flexibility for personalized and compounded products.
Q:Are there additional drugs being considered for compounding and offering?
A:There is a strong internal roadmap for additional drugs, but details are not disclosed at this time.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact number of Wegovy pill subscribers, the long-term retention rates for the Wegovy pill, and the additional drugs being considered for compounding. They also did not provide a precise answer on the potential lifetime value difference between covered and cash pay patients.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI capability
AI decision
AI tool
OB GYN
RexMD
WorkSimpli gain
balance sheet
benefit sale
bone health
cardiologist
cardiology offering
combination
contributor
decision support
demand
efficiency
experience patient
figure benefit
gain loss
health Dr
health information
history
information exchange
infrastructure priority
medicine
medium
operation
patient acquisition
pharmacy infrastructure
record
run
sign ups
tool patient
volume
LFMD Transcript
LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call reveals a mixed picture: increased losses and a decline in revenue, yet strong cash position and strategic partnerships with Novo and Lilly. The Q&A highlights promising insurance-supported programs and strategic shifts, but concerns about revenue guidance and unclear management responses persist. With no market cap data, the lack of strong catalysts and mixed financial indicators suggest a neutral stock price movement in the short term.
LifeMD, Inc. (LFMD) Q4 2025 Earnings Call Transcript
Positive3-9
The earnings call highlights strong financial performance with revenue and EBITDA growth, no debt, and a positive cash position. The Q&A reveals robust demand for the Wegovy pill, promising initial retention rates, and strategic investments in growth areas like women's health. While management was vague on some specifics, the overall sentiment remains positive due to strong financial metrics, optimistic guidance, and strategic partnerships, despite some uncertainties.
LifeMD, Inc. (LFMD) Q3 2025 Earnings Call Transcript
Unknown11-17
The earnings call reveals several concerns: a decline in weight management revenue, reduced financial guidance, and margin pressures due to shifts in business mix. Although there is optimism for 2026 and some positive developments like insurance coverage and new product lines, these are long-term prospects. The immediate financial outlook is weakened by the revised guidance and margin erosion, leading to a likely negative market reaction in the short term.
LifeMD, Inc. (LFMD) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call presents mixed signals: strong telehealth revenue growth and strategic partnerships are positive, but concerns arise from fluctuating customer acquisition costs and guidance reduction related to the RexMD business. The Q&A reveals management's evasiveness on certain metrics, which can create uncertainty. Despite positive new initiatives and raised guidance for 2025, the immediate impact is tempered by operational challenges and lack of clear answers on key metrics, resulting in a neutral sentiment.
LFMD Slides
LFMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
